Results 21 to 30 of about 65,986 (255)

BRCA 1/BRCA 2 PATHOGENIC/LIKELY PATHOGENIC VARIANT PATIENTS WITH BREAST, OVARIAN, AND OTHER CANCERS

, 2022
The demographic and clinical characteristics of patients who have BRCA 1/BRCA 2 pathogenic/likely pathogenic variants may differ from their relatives who had BRCA-related cancer.
Devrim, C., Ercan, Oe., Osman, K., Hilmi, T., Ahmet, K., Murat, S., Ilker, N. O.   +6 more
core   +2 more sources

Response of Estrogen-Receptor-Positive Metastatic Breast Cancer to Olaparib in Late-Line Therapy

Case Reports in Oncology, 2019
Monotherapy with olaparib provides significant benefits over standard therapy in patients with a germline BRCA mutation and human epidermal growth factor receptor 2 (HER2) negative metastatic breast cancer, who had two or fewer previous chemotherapeutic ...
Toko Kumeta, Ryoichi Matsunuma, Kei Yamaguchi, Ryosuke Hayami, Michiko Tsuneizumi   +4 more
doaj   +1 more source

BRCA-deficient subtype signature identifies triple negative breast cancer patients with improved survival with anthracycline/taxane chemotherapy.

, 2016
(A) Proportion of BRCA-D tumors among TNBC tumors in different CMB categories. (B) Overall survival of TNBC patients by BRCA deficiency status in the TCGA cohort.
Vikram B. Wali (3396224), Lajos Pusztai (78763), Charles Li (3396221), Weiwei Shi (139867), Rosanna Lau (380895), Balázs Győrffy (110652), Richard P. Lifton (147862), Tingting Jiang (169999), Christos Hatzis (565382), Lőrinc S. Pongor (101774), William F. Symmans (3396218)   +10 more
core   +1 more source

BRCA-associated pancreatico-biliary neoplasms: Four cases illustrating the emerging clinical impact of genotyping

, 2016
BRCA-associated pancreatico-biliary neoplasms: Four cases illustrating the emerging clinical impact of ...
Morten Ladekarl (691700), Maja Bendtsen Sharma (2793562), Andreas Carus (2793559), Lone Sunde (547072), Stephen Hamilton-Dutoit (69422)   +4 more
core   +1 more source

Comparison of Patient Susceptibility Genes Across Breast Cancer: Implications for Prognosis and Therapeutic Outcomes

Pharmacogenomics and Personalized Medicine, 2020
Shira Peleg Hasson,1 Tehillah Menes,2 Amir Sonnenblick1 1Oncology Department, Tel Aviv Sourasky Medical Center and Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel; 2Department of Surgery, Tel Aviv-Sourasky Medical Center and Sackler ...
Peleg Hasson S, Menes T, Sonnenblick A
doaj  

PARP Inhibitors for the Treatment of BRCA1/ 2-Mutated Metastatic Breast Cancer: A Systematic Review and Meta-analysis

Hematology/Oncology and Stem Cell Therapy, 2023
Background: The PARP inhibitors (PARPis) olaparib and talazoparib are currently approved for the treatment of deleterious germline BRCA1/2-mutated (gBRCA+) metastatic breast cancer (MBC).
Ranju Kunwor, Daniel P. Silver, Maysa Abu-Khalaf   +2 more
doaj   +1 more source

Practical aspects of treating relapsed BRCA-associated ovarian cancer

Медицинский совет, 2019
Ovarian cancer ranks first in the mortality causes pattern of female reproductive cancers in Russia. Treatment of relapsed ovarian cancer remains a significant challenge to practicing oncologists.
A. A. Rumyantse, A. S. Tyulyandina
doaj   +1 more source

Excellent Response to Olaparib in a Patient with Metastatic Pancreatic Adenocarcinoma with Germline BRCA1 Mutation after Progression on FOLFIRINOX: Case Report and Literature Review

Case Reports in Oncology, 2020
Metastatic pancreatic ductal adenocarcinoma (PDAC) has a dismal prognosis. Until recently, cytotoxic chemotherapy was the only treatment option. Currently, there are subgroups of patients with PDAC either with somatic or germline mutations who are ...
Jefferson Rios Pimenta, Serli Kiyomi Nakao Ueda, Renata D’Alpino Peixoto   +2 more
doaj   +1 more source

The BRCA1-A complex restricts replication fork reversal-dependent DNA repair in ATM deficient cells

Nature Communications
Ataxia Telangiectasia Mutated (ATM) kinase deficiency results in cancer susceptibility and drug hypersensitivity. Deficiency in either the BRCA1 interacting A complex or XRCC4/Ligase 4 confers resistance to Topoisomerase I or PARP1 inhibitors in ATM ...
Arindam Datta, Jessica Jackson, Yaroslav I. Morozov, Jinghan Qiu, Alessandro Vindigni, Roger A. Greenberg   +5 more
doaj   +1 more source

Cost-Effectiveness Analysis of Maintenance Olaparib in Patients with Metastatic Pancreatic Cancer and a Germline BRCA1/2 Mutation Based on the POLO Trial

Cancer Management and Research, 2020
Mei Zhan,1– 3 Hanrui Zheng,1– 3 Yu Yang,2,4 Zhiyao He,1 Ting Xu,1,3 Qiu Li2,4 1Department of Pharmacy, West China Hospital, Sichuan University, Chengdu, People’s Republic of China; 2West China Biomedical Big Data Center, Sichuan ...
Zhan M, Zheng H, Yang Y, He Z, Xu T, Li Q   +5 more
doaj